98 related articles for article (PubMed ID: 16557201)
1. Cancer screening with FDG-PET.
Ide M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):23-7. PubMed ID: 16557201
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
3. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
4. PET and cancer screening.
Yasuda S; Ide M
Ann Nucl Med; 2005 May; 19(3):167-77. PubMed ID: 15981668
[TBL] [Abstract][Full Text] [Related]
5. Application of positron emission tomography imaging to cancer screening.
Yasuda S; Ide M; Fujii H; Nakahara T; Mochizuki Y; Takahashi W; Shohtsu A
Br J Cancer; 2000 Dec; 83(12):1607-11. PubMed ID: 11104553
[TBL] [Abstract][Full Text] [Related]
6. Application of PET and PEt/CT imaging for cancer screening.
Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
[TBL] [Abstract][Full Text] [Related]
7. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
Minamimoto R; Senda M; Terauchi T; Jinnouchi S; Inoue T; Iinuma T; Inoue T; Ito K; Iwata H; Uno K; Oku S; Oguchi K; Tsukamoto E; Nakashima R; Nishizawa S; Fukuda H; Murano T; Yoshida T
Ann Nucl Med; 2011 Jan; 25(1):45-54. PubMed ID: 20953985
[TBL] [Abstract][Full Text] [Related]
8. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
9. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure.
Ghotbi N; Iwanaga M; Ohtsuru A; Ogawa Y; Yamashita S
Asian Pac J Cancer Prev; 2007; 8(1):93-7. PubMed ID: 17477780
[TBL] [Abstract][Full Text] [Related]
10. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening.
Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
Ann Nucl Med; 2007 Jan; 21(1):65-72. PubMed ID: 17373338
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C
J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
[TBL] [Abstract][Full Text] [Related]
12. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
13. [Cancer screening with PET: advantages and limitations].
Kawada S; Suzuki Y; Hinohara S; Koide S; Ono Y; Ashikaga H
Rinsho Byori; 2007 Jul; 55(7):656-67. PubMed ID: 17718062
[TBL] [Abstract][Full Text] [Related]
14. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
Metser U; Miller E; Lerman H; Even-Sapir E
AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
[TBL] [Abstract][Full Text] [Related]
15. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera.
Andrieux A; Switsers O; Chajari MH; Jacob JH; Delozier T; Gervais R; Allouache N; Laurençon V; Henry-Amar M; Bardet S
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):68-77. PubMed ID: 16557206
[TBL] [Abstract][Full Text] [Related]
17. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
[TBL] [Abstract][Full Text] [Related]
18. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey.
Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Murano T; Fukuda H; Iinuma T; Uno K; Nishizawa S; Tsukamoto E; Iwata H; Inoue T; Oguchi K; Nakashima R; Inoue T
Ann Nucl Med; 2013 Jan; 27(1):46-57. PubMed ID: 23086544
[TBL] [Abstract][Full Text] [Related]
19. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis.
Kurata S; Ishibashi M; Hiromatsu Y; Kaida H; Miyake I; Uchida M; Hayabuchi N
Ann Nucl Med; 2007 Aug; 21(6):325-30. PubMed ID: 17705011
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry.
Sengoku T; Matsumura K; Usami M; Takahashi Y; Nakayama T
Int J Clin Oncol; 2014 Dec; 19(6):989-97. PubMed ID: 24481919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
